MCID: PRS040
MIFTS: 88

Prostate Cancer

Categories: Genetic diseases, Rare diseases, Cancer diseases, Reproductive diseases

Aliases & Classifications for Prostate Cancer

MalaCards integrated aliases for Prostate Cancer:

Name: Prostate Cancer 53 37 12 24 71 36 28 13 51 40 3 14 59
Prostate Cancer, Familial 53 12 72 49 69
Prostate Carcinoma 12 24 51 14 69
Familial Prostate Cancer 49 55 28
Prostate Neoplasm 12 24 28
Prostate Cancer, Hereditary 53 49
Hereditary Prostate Cancer 12 49
Prostatic Neoplasms 41 69
Prostatic Neoplasm 12 24
Prostatic Cancer 12 24
Prostate Cancer, Familial, Susceptibility to 53
Prostate Cancer, Susceptibility to, Somatic 53
Prostate Cancer, Susceptibility to, 4 53
Prostate Cancer, Susceptibility to, 3 53
Prostate Cancer, Susceptibility to 53
Malignant Neoplasm of the Prostate 24
Prostate Cancer, Progression of 53
Malignant Tumor of the Prostate 12
Prostate Cancer, Hereditary, 5 53
Malignant Neoplasm of Prostate 69
Ngp - New Growth of Prostate 12
Malignant Tumor of Prostate 28
Prostate Cancer, Somatic 53
Prostate Cancer Somatic 53
Cancer of the Prostate 24
Tumor of the Prostate 12
Carcinoma of Prostate 12
Prostatic Carcinoma 24
Cancer of Prostate 12
Prostate Cancer 4 53
Prostate Cancer 3 53
Prca 71
Pc 71

Characteristics:

Orphanet epidemiological data:

55
familial prostate cancer
Prevalence: 1-9/100000 (United States); Age of onset: Adult;

OMIM:

53
Inheritance:
autosomal dominant form


HPO:

31
prostate cancer:
Inheritance autosomal dominant inheritance


Classifications:

Orphanet: 55  
Rare urogenital diseases


External Ids:

OMIM 53 176807
Disease Ontology 12 DOID:10283 DOID:10286
ICD10 32 C61
ICD9CM 34 185
MeSH 41 D011471
Orphanet 55 ORPHA1331
MESH via Orphanet 42 C537243
UMLS via Orphanet 70 C2931456
ICD10 via Orphanet 33 C61
MedGen 39 C0376358
KEGG 36 H00024
SNOMED-CT via HPO 65 263681008

Summaries for Prostate Cancer

MedlinePlus : 40 The prostate is the gland below a man's bladder that produces fluid for semen. Prostate cancer is common among older men. It is rare in men younger than 40. Risk factors for developing prostate cancer include being over 65 years of age, family history, and being African-American. Symptoms of prostate cancer may include Problems passing urine, such as pain, difficulty starting or stopping the stream, or dribbling Low back pain Pain with ejaculation To diagnose prostate cancer, you doctor may do a digital rectal exam to feel the prostate for lumps or anything unusual. You may also get a blood test for prostate-specific antigen (PSA). These tests are also used in prostate cancer screening, which looks for cancer before you have symptoms. If your results are abnormal, you may need more tests, such as an ultrasound, MRI, or biopsy. Treatment often depends on the stage of the cancer. How fast the cancer grows and how different it is from surrounding tissue helps determine the stage. Men with prostate cancer have many treatment options. The treatment that's best for one man may not be best for another. The options include watchful waiting, surgery, radiation therapy, hormone therapy, and chemotherapy. You may have a combination of treatments. NIH: National Cancer Institute

MalaCards based summary : Prostate Cancer, also known as prostate cancer, familial, is related to suppression of tumorigenicity 12 and squamous cell carcinoma, and has symptoms including equilibration disorder, tremor and angina pectoris. An important gene associated with Prostate Cancer is PTEN (Phosphatase And Tensin Homolog), and among its related pathways/superpathways are Prostate cancer and Transcriptional misregulation in cancer. The drugs Degarelix and Eligard have been mentioned in the context of this disorder. Affiliated tissues include the prostate, prostate and bone, and related phenotypes are cellular and endocrine/exocrine gland

UniProtKB/Swiss-Prot : 71 Prostate cancer: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma.

NIH Rare Diseases : 49 Familialprostate cancer is a cluster of prostate cancer within a family. Most cases of prostate cancer occur sporadically in people with no family history of the condition. However, approximately 5% to 10% of prostate cancer cases are believed to be primarily caused by a genetic predisposition to the condition. In many families, the underlying genetic cause is unknown; however, some of these cases are caused by changes (mutations) in the BRCA1, BRCA2, HOXB13, or several other genes. Other cases are likely due to a combination of gene(s) and other shared factors such as environment and lifestyle.High-risk cancer screening at an earlier age is typically recommended in men who have an increased risk for prostate cancer based on personal and/or family histories. Last updated: 12/7/2015

CDC : 3 Prostate cancer is the most common non-skin cancer among American men. Prostate cancers usually grow slowly. Most men with prostate cancer are older than 65 years and do not die from the disease. Finding and treating prostate cancer before symptoms occur may not improve your health or help you live longer.

Genetics Home Reference : 24 Prostate cancer is a common disease that affects men, usually in middle age or later. In this disorder, certain cells in the prostate become abnormal and multiply without control or order to form a tumor. The prostate is a gland that surrounds the male urethra and helps produce semen, the fluid that carries sperm.

Disease Ontology : 12 A male reproductive organ cancer that is located in the prostate.

Novus Biologicals : 52 Prostate cancer is the most common non-skin cancer and second most deadly cancer for men in the United States. Prostate cancer occurs when cells within the prostate grow uncontrollably and create small tumors. If untreated, cells from these tumors can spread via metastasis. Metastasis transports prostate cancer cells through the lymphatic system and bloodstream to other parts of the body where they can grow into secondary tumors. PSA, a protein produced by the prostate, is released into the bloodstream in small amounts under normal conditions. However, PSA is released in increasing amounts when the prostate is malfunctioning, as is the case with prostate cancer.

PubMed Health : 59
About prostate cancer: Prostate cancer is a malignant tumor in the prostate, a gland that is part of the male internal reproductive system. The prostate is a gland about the size of a chestnut, found between the bladder and the pelvic floor muscles. It is located right in front of the rectum. Because the prostate surrounds the urethra, it can lead to problems with urination if it becomes enlarged.

Wikipedia : 72 Prostate cancer is the development of cancer in the prostate, a gland in the male reproductive system.... more...

Description from OMIM: 176807

Related Diseases for Prostate Cancer

Diseases in the Prostate Cancer family:

Prostate Cancer, Hereditary, 1 Prostate Cancer, Hereditary, 8
Prostate Cancer, Hereditary, 3 Prostate Cancer, Hereditary, 4
Prostate Cancer, Hereditary, 5 Prostate Cancer, Hereditary, 6
Prostate Cancer, Hereditary, 7 Prostate Cancer, Hereditary, 9
Prostate Cancer, Hereditary, 10 Prostate Cancer, Hereditary, 12
Prostate Cancer, Hereditary, 13 Prostate Cancer, Hereditary, 11
Prostate Cancer, Hereditary, 14 Prostate Cancer, Hereditary, 15
Prostate Cancer, Hereditary, 2 Prostate Carcinoma in Situ

Diseases related to Prostate Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 389)
# Related Disease Score Top Affiliating Genes
1 suppression of tumorigenicity 12 31.5 AR FOLH1 KLF6 PTEN
2 squamous cell carcinoma 30.8 CDH1 CHEK2 FGFR4 PTEN
3 li-fraumeni syndrome 30.6 BRCA2 CHEK2 PTEN
4 prostate cancer, hereditary, 1 12.4
5 prostate cancer, hereditary, 2 12.4
6 prostate cancer, hereditary, 13 12.3
7 prostate cancer, hereditary, 12 12.3
8 prostate cancer, hereditary, 11 12.3
9 adenosquamous prostate carcinoma 12.2
10 prostate cancer, hereditary, x-linked 1 12.2
11 prostate cancer, hereditary, 7 12.2
12 prostate cancer, hereditary, 8 12.1
13 prostate cancer, hereditary, 4 12.0
14 prostate cancer, hereditary, x-linked 2 12.0
15 prostate cancer/brain cancer susceptibility 12.0
16 prostate cancer, hereditary, 3 12.0
17 prostate cancer, hereditary, 5 12.0
18 prostate cancer, hereditary, 6 12.0
19 prostate cancer, hereditary, 9 12.0
20 prostate cancer, hereditary, 10 12.0
21 prostate cancer, hereditary, 14 12.0
22 prostate cancer, hereditary, 15 12.0
23 prostate carcinoma in situ 12.0
24 prostate cancer, progression and metastasis of 11.9
25 prostate cancer aggressiveness quantitative trait locus on chromosome 19 11.9
26 prostatitis 11.6
27 prostate malignant phyllodes tumor 11.3
28 prostate neuroendocrine neoplasm 11.3
29 male reproductive organ cancer 11.3 AR CDH1 ELAC2 FOLH1 HOXB13 MSMB
30 prostate disease 11.3
31 radiation proctitis 11.3
32 benign prostate phyllodes tumor 11.2
33 reproductive organ cancer 11.1 AR BRCA2 CDH1 FOLH1 PTEN
34 prostate squamous cell carcinoma 11.1
35 prostate small cell carcinoma 11.1
36 hereditary breast ovarian cancer syndrome 10.9 BRCA2 CHEK2 PTEN
37 sporadic breast cancer 10.9 BRCA2 CHEK2 PTEN
38 prostate signet ring cell adenocarcinoma 10.9
39 prostate transitional cell carcinoma 10.9
40 prostate adenoid cystic carcinoma 10.9
41 prostate sarcoma 10.9
42 brca1 hereditary breast and ovarian cancer syndrome 10.9
43 brca2 hereditary breast and ovarian cancer syndrome 10.9
44 diethylstilbestrol syndrome 10.9
45 ductal carcinoma in situ 10.9 AR BRCA2 CDH1
46 ovarian cancer 1 10.9 BRCA2 CDH1 PTEN
47 female reproductive organ cancer 10.9 BRCA2 CDH1 PTEN
48 morpheaform basal cell carcinoma 10.8 AR CDH1
49 synchronous bilateral breast carcinoma 10.7 BRCA2 PTEN
50 prostatic hyperplasia, benign 10.6

Comorbidity relations with Prostate Cancer via Phenotypic Disease Network (PDN): (show all 35)


Acute Kidney Failure Anthracosis
Asbestosis Azoospermia
Balanoposthitis Bladder Cancer
Bladder Neck Obstruction Chronic Kidney Failure
Cystitis Cystica Deficiency Anemia
Disseminated Intravascular Coagulation Epididymo-Orchitis
Gout Hydronephrosis
Kidney Disease Lipoma of Spermatic Cord
Lymphadenitis Nephrolithiasis, X-Linked Recessive, with Renal Failure
Oligospermia Paralytic Ileus
Paraplegia Prostate Calculus
Prostate Carcinoma in Situ Prostate Disease
Prostatic Hypertrophy Prostatitis
Radiation Cystitis Spermatocele
Spinal Cord Disease Ureterolithiasis
Urethral Benign Neoplasm Urethral Calculus
Urethral Stricture Urethritis
Urinary Tract Obstruction

Graphical network of the top 20 diseases related to Prostate Cancer:



Diseases related to Prostate Cancer

Symptoms & Phenotypes for Prostate Cancer

Symptoms via clinical synopsis from OMIM:

53
Oncology:
early onset prostate cancer


Clinical features from OMIM:

176807

Human phenotypes related to Prostate Cancer:

31
# Description HPO Frequency HPO Source Accession
1 prostate cancer 31 HP:0012125

UMLS symptoms related to Prostate Cancer:


equilibration disorder, tremor, angina pectoris

MGI Mouse Phenotypes related to Prostate Cancer:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.28 CD82 CDH1 CHEK2 EPHB2 FGFR4 HIP1
2 endocrine/exocrine gland MP:0005379 10.21 AR BRCA2 CDH1 CHEK2 EPHB2 HIP1
3 homeostasis/metabolism MP:0005376 10.1 AR BRCA2 CD82 CDH1 CHEK2 FGFR4
4 immune system MP:0005387 10 BRCA2 CDH1 CHEK2 HIP1 MSMB MSR1
5 mortality/aging MP:0010768 10 AR BRCA2 CDH1 CHEK2 ELAC2 EPHB2
6 neoplasm MP:0002006 9.73 AR BRCA2 CD82 CDH1 CHEK2 FGFR4
7 reproductive system MP:0005389 9.44 AR BRCA2 CDH1 EPHB2 FGFR4 HIP1

Drugs & Therapeutics for Prostate Cancer

PubMedHealth treatment related to Prostate Cancer: 59

The treatment options for prostate cancer has will depend on different factors. The main ones are how aggressive the tumor is, its size and stage, the PSA levels, age, and overall health.Men who have high-risk prostate cancer will usually have their prostate surgically removed or start having radiotherapy. Radiotherapy can be done in two ways: from outside of the body (external radiotherapy) or from inside the body (internal radiotherapy, or brachytherapy).The most common side effects of radiotherapy or removing the prostate gland are accidental leakage of urine (urinary incontinence) and impotence. External radiotherapy is especially likely to cause diarrhea, and in some cases rectal inflammation which may result in bleeding and cramps.The following treatments are also possible provided that the tumor is not aggressive (low-risk prostate cancer), and remains small and inside the prostate:Active surveillance: The prostate cancer is simply monitored, and not treated right away. This strategy is based on the fact that non-aggressive prostate cancer will often grow very slowly or not at all. It is often found that the cancer has still not advanced even years after it was diagnosed. In place of treatment, the prostate is checked regularly. Treatment attempting to cure the cancer (curative treatment) is only started if the tumor starts growing. The advantage of this approach is that the side effects of surgery or radiotherapy can be avoided as long as the cancer does not grow.Watchful waiting: This strategy also starts by only monitoring the prostate cancer at first. But if the tumor starts growing, only the symptoms are treated, not the tumor itself (this is known as “palliative care). This approach is designed mainly for older men, who may also have other conditions or diseases. The risks and stress of surgery or radiotherapy could outweigh the possible benefits of this treatment.There is not much research on the advantages and disadvantages of the different treatment strategies for men who have low-risk prostate cancer. To find out more about these strategies, a study called PREFERE was started in Germany comparing a strategy of waiting with other kinds of treatments for men who have low-risk prostate cancer. The study is designed to compare the likelihood of success and the side effects of the various treatment strategies. There is no “right” or “wrong” treatment decision for men who have low-risk prostate cancer. The strategy that one man chooses will depend on factors such as his age, but will also be a matter of personal preferences and values. Some will feel it is more important to avoid side effects like impotence or incontinence as much as possible. Others will want to be very sure that the cancer has been removed, so they are willing to accept the risks associated with treatment.There are several kinds of hormonal treatments and chemotherapies available that aim to slow the growth of advanced stage prostate cancer.

FDA approved drugs:

(show all 17)
# Drug Name Active Ingredient(s) 17 Company Approval Date
1
Degarelix 17 45 degarelix Ferring Pharmaceuticals December of 2008
2
Eligard 17 45 LEUPROLIDE ACETATE Atrix Laboratories January 2002
3
Eulexin 17 FLUTAMIDE Schering-Plough June 1996
4
Iressa 17 45 GEFITINIB AstraZeneca May 2003
5
Jevtana 17 45 CABAZITAXEL sanofi aventis June 2010
6
Lupron Depot 17 45 LEUPROLIDE ACETATE TAP Pharmaceuticals/ Abbott Laboratories July 1997/ January 1996
7
Plenaxis 17 ABARELIX Praecis Pharmaceuticals December 2003
8
Provenge 17 45 sipuleucel-T Dendreon May 2010
9
Taxotere 17 45 DOCETAXEL Rhone Poulenc Rorer May 1996
10
Trelstar Depot/ Trelstar LA 17 TRIPTORELIN PAMOATE Debio Rechereche Pharmaceutique, Target Research Associates/ Debiopharm June 2000/ June 2001
11
Viadur 17 45 LEUPROLIDE ACETATE Alza March 2000
12
Xgeva 17 45 DENOSUMAB Amgen June 2013/ November 2010
13
Xofigo 17 45 RADIUM RA-223 DICHLORIDE Bayer Healthcare Pharmaceuticals May 2013
14
Xtandi 17 45 ENZALUTAMIDE Medivation August 2012
15
Zoladex 17 45 GOSERELIN ACETATE AstraZeneca January 1996
16
Zometa 17 45 ZOLEDRONIC ACID Novartis August 2001/ February 2002
17
Zytiga 17 45 ABIRATERONE ACETATE Centocor Ortho Biotech May 2011

Drugs for Prostate Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 871)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Goserelin Approved Phase 4,Phase 3,Phase 2,Phase 1 65807-02-5 5311128 47725
2
Iodine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 7553-56-2 807
3
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1 657-24-9 4091 14219
4
Leuprolide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53714-56-0 657181 3911
5
Dutasteride Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 164656-23-9 6918296 152945
6
Zoledronic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 118072-93-8 68740
7
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
8
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
9
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
10
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-22-0 6013
11
Bicalutamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 90357-06-5 2375 56069
12
Dopamine Approved Phase 4,Phase 3,Phase 1,Phase 2 51-61-6, 62-31-7 681
13
Histamine Approved, Investigational Phase 4,Phase 2 51-45-6, 75614-87-8 774
14
Lenograstim Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 135968-09-1
15
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-18-4 6010
16
Ropivacaine Approved Phase 4,Phase 3 84057-95-4 175805 71273
17
Acetaminophen Approved Phase 4,Phase 2,Phase 1 103-90-2 1983
18
Celecoxib Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 169590-42-5 2662
19
Menthol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 2216-51-5 16666
20
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 3 137-58-6 3676
21
Flutamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 13311-84-7 3397
22 sodium fluoride Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 7681-49-4
23
Somatostatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 38916-34-6, 51110-01-1 53481605
24
Finasteride Approved Phase 4,Phase 3,Phase 2 98319-26-7 57363
25
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-02-2 5743
26
Diphenhydramine Approved, Investigational Phase 4,Phase 2,Phase 1 58-73-1, 147-24-0 3100
27
Granisetron Approved, Investigational Phase 4 109889-09-0 3510
28
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
29
Ondansetron Approved Phase 4 99614-02-5 4595
30
Promethazine Approved, Investigational Phase 4,Phase 2,Phase 1 60-87-7 4927
31
Ranitidine Approved Phase 4,Phase 2 66357-59-3, 66357-35-5 3001055
32
Ciprofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2 85721-33-1 2764
33
Etidronic acid Approved Phase 4,Phase 3 2809-21-4, 7414-83-7 3305
34
Desflurane Approved Phase 4 57041-67-5 42113
35
Nitric Oxide Approved Phase 4,Phase 2 10102-43-9 145068
36
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
37
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 1994-09-7, 94-09-7 2337
38
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3 437-38-7 3345
39
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
40
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
41
Gabapentin Approved, Investigational Phase 4,Phase 3,Phase 2 60142-96-3 3446
42
gamma-Aminobutyric acid Approved, Investigational Phase 4,Phase 3,Phase 2 56-12-2 119
43
Hydromorphone Approved, Illicit Phase 4,Phase 3 466-99-9 5284570
44
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
45
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
46
Mepivacaine Approved, Vet_approved Phase 4 96-88-8 4062
47
Midazolam Approved, Illicit Phase 4,Phase 1 59467-70-8 4192
48
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 9004-61-9 53477741 24759
49
Tacrolimus Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 104987-11-3 445643 439492
50
Tadalafil Approved, Investigational Phase 4,Phase 3 171596-29-5 110635

Interventional clinical trials:

(show top 50) (show all 4089)

# Name Status NCT ID Phase Drugs
1 FINNPROSTATE Study VII: Intermittent Versus Continuous Androgen Deprivation in Patients With Advanced Prostate Cancer Unknown status NCT00293670 Phase 4 Goserelin (Zoladex)
2 Treatment of Localized Prostate Cancer With High Intensity Focused Ultrasound Using the Sonablate® 500 System in Canada Unknown status NCT00573586 Phase 4
3 Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy Unknown status NCT01379742 Phase 4
4 MR-Lymphography and Lymph Node Staging in Prostate Cancer Unknown status NCT00185029 Phase 4
5 Metformin And Longevity Unknown status NCT02511665 Phase 4 Metformin;Placebo
6 Early Detection of Prostate Cancer by FACS Unknown status NCT00524823 Phase 4
7 Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer Unknown status NCT00906269 Phase 4 Sildenafil therapy plus post-NSRRP HBO2T;Sildenafil therapy plus sham post-NSRRP HBO2T
8 Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer Completed NCT00199485 Phase 4 Angelica Sinensis
9 Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer Completed NCT01511874 Phase 4 ELIGARD 22.5mg
10 Assessment Of Dutasteride (AVODART) In Extending The Time To Progression Of Low-Risk, Localized Prostate Cancer In Men Completed NCT00363311 Phase 4 Dutasteride;Matching placebo
11 Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases Completed NCT00219219 Phase 4 Zoledronic acid
12 Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer Completed NCT00219271 Phase 4 Zoledronic acid
13 Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer Completed NCT00375765 Phase 4 Dutasteride
14 A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade Therapy Completed NCT02405858 Phase 4 Abiraterone Acetate;Prednisolone
15 Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis Completed NCT00035997 Phase 4 Zometa
16 Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy Completed NCT00237146 Phase 4 Zoledronic acid
17 A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer Completed NCT02116582 Phase 4 Enzalutamide
18 Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer Completed NCT00391690 Phase 4 Zoledronic acid
19 A Study to Evaluate the Efficacy and Tolerability of Zoledronic Acid in Patients With Metastatic Prostate Cancer Who Can be Treated With a Group of Medications Known as Bisphosphonates Completed NCT00172016 Phase 4 Zoledronic acid
20 Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis Completed NCT00237159 Phase 4 Zoledronic acid
21 Evaluation of Safety of Cabazitaxel (Jevtana) in Patients With Metastatic Hormone Refractory Prostate Cancer Completed NCT02074137 Phase 4 CABAZITAXEL XRP6258;Prednisone;Prednisolone
22 An Alternative to A Fixed Schedule In Management Of Prostate Cancer Completed NCT01056562 Phase 4
23 3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer Completed NCT01296672 Phase 4 Finasteride;Placebo
24 Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation Completed NCT00805701 Phase 4 avodart;Placebo
25 Assessment of the Efficacy, Tolerability and Pharmaco-economic Impact of Zoledronic Acid Treatment in Prostate Cancer With Bone Metastasis Completed NCT00241111 Phase 4 zoledronic acid
26 Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases Completed NCT00242554 Phase 4 Zoledronic acid
27 Study to Monitor the Effects of Androgen Suppression Treatment on the Heart Completed NCT01230905 Phase 4
28 Docetaxel in the Treatment of Hormone Refractory Prostate Cancer Completed NCT00280098 Phase 4 docetaxel
29 Casodex/Zoladex Biomarkers in Localised Prostate Cancer Completed NCT00293696 Phase 4 bicalutamide (Casodex), goserelin (Zoladex)
30 Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer Completed NCT02441894 Phase 4 CABAZITAXEL XRP6258;PEG-G-CSF;Prednisolone;Dexchlorpheniramine or Diphenhydramine;Ranitidine;Metoclopramide, Granisetron, or Ondansetron;Dexamethasone
31 A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer Completed NCT00220194 Phase 4 leuprolide acetate
32 Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX Completed NCT00590213 Phase 4 Casodex 150mg
33 Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer Completed NCT01649635 Phase 4 CABAZITAXEL (XRP6258);Prednisone;Ciprofloxacin;G-CSF (Granulocyte colony-stimulating factor)
34 Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions Completed NCT00029224 Phase 4 zoledronic acid
35 Evaluate Recovery of Testosterone for Patients Using Eligard Completed NCT01136226 Phase 4 Eligard (TM)
36 The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy Completed NCT00063609 Phase 4 zoledronic acid
37 Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration Completed NCT01161563 Phase 4 Triptorelin pamoate;Leuprolide acetate
38 Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer Completed NCT00859027 Phase 4 risedronate;placebo
39 Effect of Soy on Cognition and Hot Flashes in Men With Prostate Cancer Undergoing Testosterone Suppression Therapy Completed NCT00245518 Phase 4 Isoflavone;Placebos
40 Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy Completed NCT00470834 Phase 4 dutasteride;placebo;bicalutamide
41 Assessment of Pain and Quality of Life in Breast and Prostate Cancer Patients With Bone Metastases Completed NCT00434317 Phase 4 Zoledronic acid
42 Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer Completed NCT00334139 Phase 4 Zoledronic Acid
43 Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer Completed NCT00953277 Phase 4
44 MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism Completed NCT02102646 Phase 4 Triptorelin
45 Global Performance Evaluation of the AMS CONTINUUM™ Device Completed NCT01083199 Phase 4
46 The Effect of Propofol Based Total Intravenous Anesthesia on Oxidative Stress and Nitric Oxide Completed NCT02149628 Phase 4 propofol;Desflurane
47 The Use of Thermal Suits as Preventing Hypothermia During Surgery Completed NCT01571544 Phase 4
48 The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function Completed NCT01547416 Phase 4 epidural 250mL of 0.2% ropivacaine and 2 μg/mL of fentanyl, 5 mL/hr continuous infusion and 0.5 mL bolus dose;no epidural drug administered
49 Hydroxyethyl Starch and Renal Function After Radical Prostatectomy Completed NCT01486563 Phase 4 Voluven (Hydroxyethyl starch 130/0,4);Sodium Chloride 9 mg/ml
50 Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy? Completed NCT00982800 Phase 4 Gabapentin;Placebo Sugar Pill

Search NIH Clinical Center for Prostate Cancer

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Prostate Cancer cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Prostate Cancer:
Alescat, autologous lymphocyte-based therapy for the treatment of solid cancers

Cochrane evidence based reviews: prostatic neoplasms

Genetic Tests for Prostate Cancer

Genetic tests related to Prostate Cancer:

# Genetic test Affiliating Genes
1 Malignant Tumor of Prostate 28 AR BRCA2 CD82 CDH1 CHEK2 HIP1 KLF6 MAD1L1 MSR1 MXI1 PTEN ZFHX3
2 Familial Prostate Cancer 28
3 Prostate Cancer 28
4 Prostate Neoplasm 28

Anatomical Context for Prostate Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Prostate Cancer:

18
The Prostate

MalaCards organs/tissues related to Prostate Cancer:

38
Prostate, Bone, Breast, Lymph Node, Testes, Lung, Endothelial

Publications for Prostate Cancer

Articles related to Prostate Cancer:

(show top 50) (show all 13555)
# Title Authors Year
1
Behaviour change techniques in physical activity interventions for men with prostate cancer: A systematic review. ( 29446325 )
2018
2
New prostate cancer grade grouping system predicts survival after radical prostatectomy. ( 29447924 )
2018
3
An integrative review exploring black men of African and Caribbean backgrounds, their fears of prostate cancer and their attitudes towards screening. ( 29444301 )
2018
4
Penile Metastasis from Prostate Cancer Presenting as Malignant Priapism Detected Using Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography. ( 29430118 )
2018
5
Local recurrence on PET/CT with<sup>11</sup>C-choline following brachytherapy for prostate cancer: tracer uptake pattern. ( 29444756 )
2018
6
Procyanidin B2 3,3a8^-di-O-gallate induces oxidative stress-mediated cell death in prostate cancer cells via inhibiting MAP kinase phosphatase activity and activating ERK1/2 and AMPK. ( 28876465 )
2018
7
Anti-oxidants as chemopreventive agents in prostate cancer: A gap between preclinical and clinical studies. ( 29446748 )
2018
8
Dioxin Exposure in the Manufacture of Pesticide Production as a Risk Factor for Death from Prostate Cancer: A Meta-analysis. ( 29445624 )
2018
9
Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. ( 29105802 )
2018
10
Selective androgen receptor modulator S42 suppresses prostate cancer cell proliferation. ( 29444261 )
2018
11
Surgeon-Led Prostate Cancer Lymph Node Staging: Pathologic Outcomes Stratified by Robot-Assisted Dissection Templates and Patient Selection. ( 29446205 )
2018
12
Lenalidomide decreased the PSA level for castration-resistant prostate cancer: a case report. ( 29445483 )
2018
13
Discovery and optimization of 1-(1H-indol-1-yl)ethanone derivatives as CBP/EP300 bromodomain inhibitors for the treatment of castration-resistant prostate cancer. ( 29448139 )
2018
14
Quantitative perineural invasion is a prognostic marker in prostate cancer. ( 29448999 )
2018
15
TRIM36, a novel androgen-responsive gene, enhances anti-androgen efficacy against prostate cancer by inhibiting MAPK/ERK signaling pathways. ( 29449534 )
2018
16
Long noncoding RNA PVT1 promotes EMT via mediating microRNA-186 targeting of Twist1 in prostate cancer. ( 29452232 )
2018
17
Prospective comparative study of<sup>18</sup>F-sodium fluoride PET/CT and planar bone scintigraphy for treatment response assessment of bone metastases in patients with prostate cancer. ( 29447047 )
2018
18
Introducing a simple model system for binding studies of known and novel inhibitors of AMPK: a therapeutic target for prostate cancer. ( 29447108 )
2018
19
Volumetric-based image guidance is superior to marker-based alignments for stereotactic body radiotherapy of prostate cancer. ( 29450961 )
2018
20
Metastatic prostate cancer with bone marrow infiltration mimicking multiple myeloma. ( 29445461 )
2018
21
Isorhapontigenin induced cell growth inhibition and apoptosis by targeting EGFR-related pathways in prostate cancer. ( 28422286 )
2018
22
Dual inhibition of BRD4 and PI3K by SF2523 suppresses human prostate cancer cell growth inA vitro and inA vivo. ( 29133261 )
2018
23
Prostate cancer-associated polyarteritis nodosa: improvement of clinical manifestations after prostatectomy. ( 29352851 )
2018
24
The use of polysulfated polysaccharides heparin like compounds, glycosaminoglycans and Vitamin B17 as a possible treatment for prostate cancer. ( 29447928 )
2018
25
Role of MRI-targeted Biopsy in Detection of Prostate Cancer Harbouring Adverse Pathological Features of Intraductal Carcinoma and Invasive Cribriform Carcinoma. ( 29408568 )
2018
26
Protein arginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth. ( 27546619 )
2017
27
ALDH1A3 correlates with luminal phenotype in prostate cancer. ( 28443495 )
2017
28
SKP2 loss destabilizes EZH2 by promoting TRAF6-mediated ubiquitination to suppress prostate cancer. ( 27869166 )
2017
29
Primary bone lymphoma presenting as skeletal lesions in a patient recently treated for prostate cancer. ( 29164979 )
2017
30
Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention Trial. ( 28317149 )
2017
31
ALKBH7 Variant Related to Prostate Cancer Exhibits Altered Substrate Binding. ( 28231280 )
2017
32
Circulating mRNAs and miRNAs as candidate markers for the diagnosis and prognosis of prostate cancer. ( 28910345 )
2017
33
Collapsin response mediator protein-1 (CRMP1) acts as an invasion and metastasis suppressor of prostate cancer via its suppression of epithelial-mesenchymal transition and remodeling of actin cytoskeleton organization. ( 27321179 )
2017
34
MicroRNA-30d promotes angiogenesis and tumor growth via MYPT1/c-JUN/VEGFA pathway and predicts aggressive outcome in prostate cancer. ( 28241827 )
2017
35
Long noncoding RNA ZEB1-AS1 epigenetically regulates the expressions of ZEB1 and downstream molecules in prostate cancer. ( 28830551 )
2017
36
Arenobufagin: A potential novel opportunity for prostate cancer treatment - Intriguing mechanistic data but some questions on in vivo translatability. ( 28951298 )
2017
37
PTTG1, A novel androgen responsive gene is required for androgen-induced prostate cancer cell growth and invasion. ( 27756608 )
2017
38
Docetaxel-Loaded Nanoparticles Assembled from I^-Cyclodextrin/Calixarene Giant Surfactants: Physicochemical Properties and Cytotoxic Effect in Prostate Cancer and Glioblastoma Cells. ( 28533751 )
2017
39
Androgen-deprivation therapy with enzalutamide enhances prostate cancer metastasis via decreasing the EPHB6 suppressor expression. ( 28826721 )
2017
40
Reply from Authors re: Jens Uwe Stolzenburg, Iason Kyriazis, Evangelos Liatsikos. Postoperative Lymphocele Formation after Pelvic Lymph Node Dissection at the Time of Radical Prostatectomy Should Not Be Considered an Inevitable Consequence of the Approach. Eur Urol 2017;71:159-60: Which Lymphatic Vessels Have To Be Secured During Pelvic Lymph Node Dissection for Prostate Cancer? ( 27666998 )
2017
41
MicroRNA-590-3p promotes cell proliferation and invasion by targeting inositol polyphosphate 4-phosphatase type II in human prostate cancer cells. ( 28345464 )
2017
42
Inhibition of the insulin-like growth factor-1 receptor potentiates acute effects of castration in a rat model for prostate cancer growth in bone. ( 28447314 )
2017
43
Loss of hSef promotes metastasis through upregulation of EMT in prostate cancer. ( 28073170 )
2017
44
Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment. ( 28532278 )
2017
45
The ErbB family and androgen receptor signaling are targets ofA Celecoxib in prostate cancer. ( 28450158 )
2017
46
Cumulative incidence and predictive factors of radiation cystitis in patients with localized prostate cancer. ( 29169704 )
2017
47
Androgen receptor-regulated miRNA-193a-3p targets AJUBA to promote prostate cancer cell migration. ( 28422308 )
2017
48
Cellular interactions of the phosphorylated form of AKT in prostate cancer. ( 28300578 )
2017
49
The Diagnostic Significance of Serum Alcohol Dehydrogenase Isoenzymes and Aldehyde Dehydrogenase Activity in Prostate Cancer Patients. ( 28870918 )
2017
50
1,25(OH)2D3 disrupts glucose metabolism in prostate cancer cells leading to a truncation of the TCA cycle and inhibition of TXNIP expression. ( 28651973 )
2017